1391426-22-4

Basic information

• Product Name: N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine
• Synonyms: N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine;LYS05;lys05(free base)/lys01;LYS01 free base
• CAS NO: 1391426-22-4
• Molecular Formula: C23H23Cl2N5
• Molecular Weight: 440.36822
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1391426-22-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 657.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.356±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly, Heated), Methanol (Slightly, Heated)
• PKA: 8.23±0.50(Predicted)
• CAS DataBase Reference: N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine(1391426-22-4)
• EPA Substance Registry System: N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine(1391426-22-4)

Safety Data

• Hazardous Substances Data: 1391426-22-4(Hazardous Substances Data)

Usage

Description

N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine is a complex organic compound with a unique chemical structure. It is characterized by its quinolinyl groups and amine functionalities, which contribute to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine is used as an autophagy inhibitor for its ability to remove the protective mechanisms of cancer cells from various biological stresses. This inhibition can make cancer cells more susceptible to the effects of other treatments, potentially improving the efficacy of cancer therapies.
Used in Anticancer Applications:
As an autophagy inhibitor, N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine can be employed in the development of novel anticancer drugs. By targeting and inhibiting autophagy, this compound may enhance the effectiveness of existing cancer treatments and provide a new avenue for cancer research and drug development.
Used in Drug Delivery Systems:
Similar to other bioactive compounds, N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine could potentially be incorporated into drug delivery systems to improve its bioavailability and targeting capabilities. This may involve the use of nanoparticles or other advanced drug delivery technologies to ensure that the compound reaches its intended site of action within the body, maximizing its therapeutic potential while minimizing side effects.

Upstream product

• 86-98-6 4,7-dichloroquinoline 
• 4097-88-5 1,5-diamino-3-azamethylpentane 
• 86-99-7 7-chloro-4-hydroxylquinoline 
• 98519-65-4 7-chloro-4-bromo-quinoline 

Relevant articles and documents

Potent Antimalarial Activity of Two Arenes Linked with Triamine Designed to Have Multiple Interactions with Heme

Based on the idea that compounds designed to exhibit high affinity for heme would block hemozoin formation, a critical heme-detoxification process for malarial parasites, we synthesized a series of compounds with two π-conjugated moieties at terminal amino groups of triamine. These compounds exhibited moderate to high antimalarial activities in vitro toward both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. In a P. berghei-infected mouse model, 3a and 12a showed potent antimalarial activities compared to artesunate, as well as a prolonged duration of antimalarial effect. We found a good correlation between protective activity against hemin degradation and antimalarial activity. Compounds 8b and 3a strongly inhibited hemozoin formation catalyzed by heme detoxification protein.

NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM AND THEIR USE

The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent represent additional aspects of the invention. Methods of treating disease states and/or conditions in which inhibition of autophagy plays a favorable treatment role including rheumatoid arthritis, malaria, antiphospholipid antibody syndrome, lupus, chronic urticaria and Sjogren's disease, with compounds according to the present invention represent additional aspects of the invention.